caa a22 4500 445332301 CHVBK 20180317142741.0 cr unu---uuuuu 170323e20110601xx s 000 0 eng 10.1007/s10198-010-0281-z doi (NATIONALLICENCE)springer-10.1007/s10198-010-0281-z Health care costs and their predictors of inflammatory bowel diseases in Germany [Elektronische Daten] [Anne Prenzler, Bernd Bokemeyer, J.-Matthias von der Schulenburg, Thomas Mittendorf] Objectives: Detailed cost studies of inflammatory bowel diseases (IBD) for Germany are limited. Aim of this study was to collect resource-use data related to IBD via a cross-sectional study, to quantify these from the perspective of the Statutory Health Insurance (SHI) and to identify cost-driving factors. Methods: Patients with Crohn's disease (CD) or ulcerative colitis (UC) from 24 gastroenterological specialists' practices and two hospitals were enrolled in an internet-based database between March 2006 and July 2007. Outpatient services, inpatient visits as well as medication usage were recorded and evaluated from the perspective of the SHI for 2007. Disease severity was measured by the Crohn's Disease Activity Index (CDAI) and the Colitis Activity Index (CAI), respectively. Extensive statistical analyses including generalized linear modeling (gamma model with the log link) to identify cost-driving factors were performed. Results: Data from 1,030 patients with IBD (CD: 511; UC: 519) were collected. On average a patient with CD incurs annual costs of EUR3,767 (±5,895 (SD)) (among those 68.5% medication; 20.5% inpatient) and an average patient with UC incurs EUR 2,478 (±4,591) (74% medication; 10% inpatient), whereas 10% of the patient with IBD account for 49% (CD: 50%; UC: 46%) of the costs. The regression analysis showed that especially the use of TNF-alpha-inhibitors, inpatient stays, gender as well as the severity status has a significant influence on costs. Further disease-specific impact factors were identified. Conclusions: This is the first study to calculate costs due to CD and UC from the perspective of the SHI in Germany and to identify cost-driving factors. It confirms a high economic burden of IBD to payers and society. Springer-Verlag, 2010 Cost analyses nationallicence Inflammatory bowel diseases nationallicence Germany nationallicence Generalized linear models nationallicence Cost of illness nationallicence Prenzler Anne Leibniz University Hannover, Center for Health Economics, Koenigsworther Platz 1, 30167, Hannover, Germany aut Bokemeyer Bernd Gastroenterology Practice Minden, Minden, Germany aut von der Schulenburg J.-Matthias Leibniz University Hannover, Center for Health Economics, Koenigsworther Platz 1, 30167, Hannover, Germany aut Mittendorf Thomas Leibniz University Hannover, Center for Health Economics, Koenigsworther Platz 1, 30167, Hannover, Germany aut The European Journal of Health Economics Springer-Verlag 12/3(2011-06-01), 273-283 1618-7598 12:3<273 2011 12 10198 https://doi.org/10.1007/s10198-010-0281-z text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10198-010-0281-z text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Prenzler Anne Leibniz University Hannover, Center for Health Economics, Koenigsworther Platz 1, 30167, Hannover, Germany aut NATIONALLICENCE 700 1- Bokemeyer Bernd Gastroenterology Practice Minden, Minden, Germany aut NATIONALLICENCE 700 1- von der Schulenburg J.-Matthias Leibniz University Hannover, Center for Health Economics, Koenigsworther Platz 1, 30167, Hannover, Germany aut NATIONALLICENCE 700 1- Mittendorf Thomas Leibniz University Hannover, Center for Health Economics, Koenigsworther Platz 1, 30167, Hannover, Germany aut NATIONALLICENCE 773 0- The European Journal of Health Economics Springer-Verlag 12/3(2011-06-01), 273-283 1618-7598 12:3<273 2011 12 10198 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer